INTERCYTEX, the regenerative medicine firm, has announced that trials of its leg ulcer treatment have failed.

The phase III trial of Cyzact, conducted in the US, the UK and Canada, failed to show a significant increase in complete wound closure at up to 12 weeks compared to the standard treatment of a four layer compression bandage.

The Manchester-based company said in a statement to the stock market that no further work on Cyzact is planned and that it will “review all strategic options”.

“......for the full story register now for free or login below...